These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28697774)

  • 1. The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction.
    Wang MT; Lin SC; Tang PL; Hung WT; Cheng CC; Yang JS; Chang HT; Liu CP; Mar GY; Huang WC
    Cardiovasc Diabetol; 2017 Jul; 16(1):89. PubMed ID: 28697774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of DPP-4 inhibitors on cardiovascular outcomes in patients with type 2 diabetes and end-stage renal disease.
    Chan SY; Ou SM; Chen YT; Shih CJ
    Int J Cardiol; 2016 Sep; 218():170-175. PubMed ID: 27236110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
    Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
    J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study.
    Chen DY; Wang SH; Mao CT; Tsai ML; Lin YS; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Chen TH
    Int J Cardiol; 2015 Feb; 181():200-6. PubMed ID: 25528312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure.
    Ou SM; Chen HT; Kuo SC; Chen TJ; Shih CJ; Chen YT
    Heart; 2017 Mar; 103(6):414-420. PubMed ID: 27647170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden.
    Svanström H; Ueda P; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Pasternak B
    Lancet Diabetes Endocrinol; 2019 Feb; 7(2):106-114. PubMed ID: 30527909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy.
    Yen FS; Chiang JH; Pan CW; Lin BJ; Wei JC; Hsu CC
    Diabetes Res Clin Pract; 2018 Jun; 140():279-287. PubMed ID: 29654814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death.
    Yu OH; Yin H; Azoulay L
    Can J Diabetes; 2015 Oct; 39(5):383-9. PubMed ID: 25840943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
    Scheller NM; Mogensen UM; Andersson C; Vaag A; Torp-Pedersen C
    Diabetes Obes Metab; 2014 Mar; 16(3):231-6. PubMed ID: 24020750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study.
    Driessen JH; van den Bergh JP; van Onzenoort HA; Henry RM; Leufkens HG; de Vries F
    Diabetes Obes Metab; 2017 Mar; 19(3):421-428. PubMed ID: 27943565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome and Cardiac Function in Patients With Diabetes and Heart Failure　- Insights From the Ibaraki Cardiac Assessment Study-Heart Failure (ICAS-HF) Registry.
    Yamamoto M; Seo Y; Ishizu T; Nishi I; Hamada-Harimura Y; Machino-Ohtsuka T; Sato K; Sai S; Sugano A; Obara K; Aonuma K
    Circ J; 2017 Oct; 81(11):1662-1669. PubMed ID: 28592726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Post-TKA Acute Myocardial Infarction in Patients With a History of Myocardial Infarction or Coronary Stent.
    Kumar A; Tsai WC; Tan TS; Chiu LT; Kung PT; Lo CK; Ku MC
    Clin Orthop Relat Res; 2016 Feb; 474(2):479-86. PubMed ID: 26566978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus.
    Lyu YS; Oh S; Kim JH; Kim SY; Jeong MH
    Cardiovasc Diabetol; 2023 Jul; 22(1):185. PubMed ID: 37481509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study.
    Chen YC; Chen TH; Sun CC; Chen JY; Chang SS; Yeung L; Tsai YW
    Acta Diabetol; 2020 Oct; 57(10):1181-1192. PubMed ID: 32318876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan.
    Wang SH; Chen DY; Lin YS; Mao CT; Tsai ML; Hsieh MJ; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Chen TH
    PLoS One; 2015; 10(6):e0131122. PubMed ID: 26115092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
    Sütő G; Molnár GA; Rokszin G; Fábián I; Kiss Z; Szekanecz Z; Poór G; Jermendy G; Kempler P; Wittmann I
    BMJ Open Diabetes Res Care; 2021 Jan; 9(1):. PubMed ID: 33472796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitors reduce the incidence of first cardiovascular events in Japanese diabetic patients.
    Soejima H; Ogawa H; Morimoto T; Okada S; Matsumoto C; Nakayama M; Masuda I; Jinnouchi H; Waki M; Saito Y;
    Heart Vessels; 2023 Nov; 38(11):1371-1379. PubMed ID: 37522902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Sitagliptin with cardiovascular outcome in diabetic patients: a nationwide cohort study.
    Yang TY; Liaw YP; Huang JY; Chang HR; Chang KW; Ueng KC
    Acta Diabetol; 2016 Jun; 53(3):461-8. PubMed ID: 26687195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
    Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Frederich R; Wiviott SD; Hoffman EB; Cavender MA; Udell JA; Desai NR; Mosenzon O; McGuire DK; Ray KK; Leiter LA; Raz I;
    N Engl J Med; 2013 Oct; 369(14):1317-26. PubMed ID: 23992601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.